{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:21:31Z","timestamp":1792581691723,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00417-019-04306-1","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T10:25:11Z","timestamp":1554114311000},"page":"1183-1189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment"],"prefix":"10.1007","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-6353","authenticated-orcid":false,"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"4306_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon N, O\u2019Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477\u2013485","journal-title":"Arch Ophthalmol"},{"key":"4306_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"4306_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"4306_CR4","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1136\/bjophthalmol-2015-308264","volume":"100","author":"S Fauser","year":"2016","unstructured":"Fauser S, Muether PS (2016) Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol 100:1494\u20131498","journal-title":"Br J Ophthalmol"},{"key":"4306_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","volume":"192","author":"M Okada","year":"2018","unstructured":"Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH (2018) The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol 192:184\u2013197","journal-title":"Am J Ophthalmol"},{"key":"4306_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-307299","volume":"100","author":"K Hatz","year":"2016","unstructured":"Hatz K, Prunte C (2016) Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 100:1341\u20131345","journal-title":"Br J Ophthalmol"},{"key":"4306_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ophtha.2008.10.029","volume":"116","author":"WE Smiddy","year":"2009","unstructured":"Smiddy WE (2009) Economic implications of current age-related macular degeneration treatments. Ophthalmology 116:481\u2013487","journal-title":"Ophthalmology"},{"key":"4306_CR8","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00417-016-3384-0","volume":"254","author":"H Senra","year":"2016","unstructured":"Senra H, Ali Z, Balaskas K, Aslam T (2016) Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefes Arch Clin Exp Ophthalmol 254:1873\u20131880","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4306_CR9","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","volume":"122","author":"Y Kuroda","year":"2015","unstructured":"Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303\u20132310","journal-title":"Ophthalmology"},{"key":"4306_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/jop.2016.0098","volume":"33","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Lee DW, Kim CG, Kim JW (2017) Incidence and timing of the first recurrence in neovascular age-related macular degeneration: comparison between ranibizumab and aflibercept. J Ocul Pharmacol Ther 33:445\u2013451","journal-title":"J Ocul Pharmacol Ther"},{"key":"4306_CR11","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1097\/IAE.0000000000001383","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2017) Recurrence in patients with type 3 neovascularization (retinal angiomatous proliferation) after intravitreal ranibizumab. Retina 37:1508\u20131515","journal-title":"Retina"},{"key":"4306_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/IAE.0b013e3181669504","volume":"28","author":"KB Freund","year":"2008","unstructured":"Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L (2008) Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28:201\u2013211","journal-title":"Retina"},{"key":"4306_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","volume":"21","author":"LA Yannuzzi","year":"2001","unstructured":"Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416\u2013434","journal-title":"Retina"},{"key":"4306_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","volume":"35","author":"A Nagiel","year":"2015","unstructured":"Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, Ameri H, Querques G, Freund KB (2015) Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 35:638\u2013647","journal-title":"Retina"},{"issue":"Suppl 1","key":"4306_CR15","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1097\/IAE.0000000000001268","volume":"36","author":"D Su","year":"2016","unstructured":"Su D, Lin S, Phasukkijwatana N, Chen X, Tan A, Freund KB, Sarraf D (2016) An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography. Retina 36(Suppl 1):S40\u2013S49","journal-title":"Retina"},{"key":"4306_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/IAE.0000000000000374","volume":"35","author":"L Xu","year":"2015","unstructured":"Xu L, Mrejen S, Jung JJ, Gallego-Pinazo R, Thompson D, Marsiglia M, Freund KB (2015) Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina 35:176\u2013186","journal-title":"Retina"},{"key":"4306_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:150\u2013161","journal-title":"Ophthalmology"},{"key":"4306_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","volume":"121","author":"FG Holz","year":"2014","unstructured":"Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M (2014) Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology 121:1079\u20131091","journal-title":"Ophthalmology"},{"key":"4306_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","volume":"123","author":"E Daniel","year":"2016","unstructured":"Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG (2016) Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology 123:609\u2013616","journal-title":"Ophthalmology"},{"key":"4306_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/jcm4071380","volume":"4","author":"S Mrejen","year":"2015","unstructured":"Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R, Yannuzzi N, Xu L, Marsiglia M, Boddu S, Freund KB (2015) Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med 4:1380\u20131402","journal-title":"J Clin Med"},{"key":"4306_CR21","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","volume":"36","author":"NS Abdelfattah","year":"2016","unstructured":"Abdelfattah NS, Zhang H, Boyer DS, Sadda SR (2016) Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina 36:1843\u20131850","journal-title":"Retina"},{"key":"4306_CR22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583","journal-title":"Am J Ophthalmol"},{"key":"4306_CR23","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623\u20131628","journal-title":"Br J Ophthalmol"},{"key":"4306_CR24","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1097\/IAE.0000000000000952","volume":"36","author":"YK Kim","year":"2016","unstructured":"Kim YK, Park SJ, Woo SJ, Park KH (2016) Choroidal thickness change after intravitreal anti-vascular endothelial growth factor treatment in retinal angiomatous proliferation and its recurrence. Retina 36:1516\u20131526","journal-title":"Retina"},{"key":"4306_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","volume":"29","author":"DL Nickla","year":"2010","unstructured":"Nickla DL, Wallman J (2010) The multifunctional choroid. Prog Retin Eye Res 29:144\u2013168","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"4306_CR26","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00417-018-4061-2","volume":"256","author":"D Barthelmes","year":"2018","unstructured":"Barthelmes D, Nguyen V, Walton R, Gillies MC, Daien V (2018) A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project. Graefes Arch Clin Exp Ophthalmol 256(10):1839\u20131846. \n                    https:\/\/doi.org\/10.1007\/s00417-018-4061-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"4306_CR27","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1097\/IAE.0000000000001862","volume":"38","author":"HJ Cho","year":"2017","unstructured":"Cho HJ, Hwang HJ, Kim HS, Han JI, Lee DW, Kim JW (2017) Intravitreal aflibercept and ranibizumab injections for type 3 neovascularization. Retina 38(11):2150\u20132158. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000001862","journal-title":"Retina"},{"key":"4306_CR28","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00417-009-1089-3","volume":"247","author":"L Konstantinidis","year":"2009","unstructured":"Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A (2009) Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 247:1165\u20131171","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4306_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/00006982-200509000-00005","volume":"25","author":"NE Gross","year":"2005","unstructured":"Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA (2005) Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25:713\u2013718","journal-title":"Retina"},{"key":"4306_CR30","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1111\/aos.12748","volume":"94","author":"YS Chang","year":"2016","unstructured":"Chang YS, Kim JH, Yoo SJ, Lew YJ, Kim J (2016) Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population. Acta Ophthalmol 94:e49\u2013e53","journal-title":"Acta Ophthalmol"},{"key":"4306_CR31","doi-asserted-by":"publisher","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim HS (2018) Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization. Retina doi: \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000002239","DOI":"10.1097\/IAE.0000000000002239"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-019-04306-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T23:15:51Z","timestamp":1585610151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-019-04306-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4306"],"URL":"https:\/\/doi.org\/10.1007\/s00417-019-04306-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of Kim\u2019s Eye Hospital (Seoul, South Korea). This study was conducted in accordance with the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not obtained in this study. Identifying information about participants was not presented in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was supported by Kim\u2019s Eye Hospital Research Center.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}}]}}